USA flag logo/image

An Official Website of the United States Government

Zebrafish Tauopathy Model for Drug Screening and Target Validation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80220
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
AG028245
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ZYGOGEN, LLC
58 Edgewood Avenue 1st Floor, Room 122 ATLANTA, GA 30303
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Zebrafish Tauopathy Model for Drug Screening and Target Validation
Agency: HHS
Contract: 1R43AG028245-01
Award Amount: $153,320.00
 

Abstract:

DESCRIPTION (provided by applicant): Description: Several neurological disorders, including Alzheimer's disease and frontotemporal dementia with parkinsonism (FTDP) are characterized in part by neurofibrillary tangles made up primarily of the protein tau. While useful mammalian models of tauopathy have been developed, a need exists for a vertebrate model of tauopathy that is amenable to high throughput drug screening and rapid target validation. We propose to create transgenic zebrafish that express human tau specifically in neurons. In Phase I, the consequences of transient overexpression of tau will be analyzed by immnohistochemistry, western blot analysis, and visualization of fluorescent neurons in living embryos. Stable transgenic lines will also be generated. In Phase II, the assay will be further validated and automated in preparation for screening compound libraries. The eventual goal is to identify compounds that can protect neurons from tau-induced toxicity. In addition, zebrafish genes that affect tau aggregate formation can be rapidly identified, potentially opening up new avenues for Alzheimer's disease and FTDP drug discovery. The assay will be marketed to pharmaceutical companies to aid their drug discovery efforts. In addition, neuroprotective compounds identified using the assay will be developed as therapeutics for neurological disorders. Relevance: The purpose of this proposal is to accelerate drug discovery for devastating neurological diseases, such as Alzheimer's disease. We propose to do this by developing a new animal model of neurological disease that can be used to screen a larger number of compounds than is currently possible.

Principal Investigator:

Amy L. Rubinstein
4045237309
amy@zygogen.com

Business Contact:

Sawczuk
4045237309
NINA@ZYGOGEN.COM
Small Business Information at Submission:

ZYGOGEN, LLC
ZYGOGEN, LLC 24 PEACHTREE CENTER AVE, KELL HALL 520 ATLANTA, GA 30303

EIN/Tax ID: 582484200
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No